-
1
-
-
40949127088
-
Myelodysplastic syndromes: Biology and treatment
-
4th Edition. Hoffman R Ed, Elsevier, Churchill Livingston Publishers, Philadelphia
-
DE ANGELO D, STONE R: Myelodysplastic syndromes: biology and treatment. In: Hoffman: Hematology: Basic Principles and Practice, 4th Edition. Hoffman R (Ed.), Elsevier, Churchill Livingston Publishers, Philadelphia (2005):67.
-
(2005)
Hoffman: Hematology: Basic Principles and Practice
, pp. 67
-
-
DE ANGELO, D.1
STONE, R.2
-
2
-
-
0017162163
-
Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative groups
-
BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative groups. Br. J. Haematol. (1976) 33:451-458.
-
(1976)
Br. J. Haematol
, vol.33
, pp. 451-458
-
-
BENNETT, J.M.1
CATOVSKY, D.2
DANIEL, M.T.3
-
3
-
-
0036786901
-
The World Health Organization (WHO) classification of the myeloid neoplasms
-
VARDIMAN JW, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100:2292-2302.
-
(2002)
Blood
, vol.100
, pp. 2292-2302
-
-
VARDIMAN, J.W.1
HARRIS, N.L.2
BRUNNING, R.D.3
-
4
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088.
-
(1997)
Blood
, vol.89
, pp. 2079-2088
-
-
GREENBERG, P.1
COX, C.2
LEBEAU, M.M.3
-
5
-
-
33947265592
-
Recent advances in myelodysplastic syndromes
-
SHADDUCK R, LATSKO J, ROSSETTI J et al.: Recent advances in myelodysplastic syndromes. Exp. Haematol. (2007) 35:137-143.
-
(2007)
Exp. Haematol
, vol.35
, pp. 137-143
-
-
SHADDUCK, R.1
LATSKO, J.2
ROSSETTI, J.3
-
6
-
-
0001583359
-
The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice
-
SORM F, VESELY J: The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice. Neoplasma (1964) 11:123.
-
(1964)
Neoplasma
, vol.11
, pp. 123
-
-
SORM, F.1
VESELY, J.2
-
7
-
-
0142216208
-
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
-
LEONE G, VOSO M, TEOFILI L et al.: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin. Immunol. (2003) 109:89-102.
-
(2003)
Clin. Immunol
, vol.109
, pp. 89-102
-
-
LEONE, G.1
VOSO, M.2
TEOFILI, L.3
-
10
-
-
0033988813
-
DNA methyltransferase DNMT1 associates with histone deacetylase activity
-
FUKS F, BURGERS WA, BREHM A et al.: DNA methyltransferase DNMT1 associates with histone deacetylase activity. Nat. Genet. (2000) 24:88-91.
-
(2000)
Nat. Genet
, vol.24
, pp. 88-91
-
-
FUKS, F.1
BURGERS, W.A.2
BREHM, A.3
-
11
-
-
24344435916
-
-
ASIF M, SIDDIQUI A, J SCOTT L: Azacitidine in myelodysplastic syndromes. Drugs (2005) 65:1781-1789.
-
ASIF M, SIDDIQUI A, J SCOTT L: Azacitidine in myelodysplastic syndromes. Drugs (2005) 65:1781-1789.
-
-
-
-
12
-
-
0029013514
-
Induction of apoptosis by 5-azacitidine: Drug concentration-dependent differences in cell cycle specificity
-
MURAKAMI T, LI X, GONG J et al.: Induction of apoptosis by 5-azacitidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. (1995) 55:3093-3098.
-
(1995)
Cancer Res
, vol.55
, pp. 3093-3098
-
-
MURAKAMI, T.1
LI, X.2
GONG, J.3
-
13
-
-
0043023499
-
Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia
-
LOPEZ-KARPOVITCH X, BARRALES-BENITEZ O, FLORES M et al.: Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. Cytokine (2002) 20:154-162.
-
(2002)
Cytokine
, vol.20
, pp. 154-162
-
-
LOPEZ-KARPOVITCH, X.1
BARRALES-BENITEZ, O.2
FLORES, M.3
-
14
-
-
17644404081
-
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes
-
MARCUCCI G, SILVERMAN L, ELLER M et al.: Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J. Clin. Pharmacol. (2005) 45:597-602.
-
(2005)
J. Clin. Pharmacol
, vol.45
, pp. 597-602
-
-
MARCUCCI, G.1
SILVERMAN, L.2
ELLER, M.3
-
15
-
-
40949101902
-
An oral dosage formulation of azacitidine: A pilot pharmacokinetic study
-
WARD MR, STOLTZ ML, ETTER JB et al.: An oral dosage formulation of azacitidine: a pilot pharmacokinetic study. ASCO Annual Meeting Proceedings (2007) 25:7084.
-
(2007)
ASCO Annual Meeting Proceedings
, vol.25
, pp. 7084
-
-
WARD, M.R.1
STOLTZ, M.L.2
ETTER, J.B.3
-
16
-
-
0027154222
-
Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
-
SILVERMAN LR, HOLLAND JF, WEINBERG RS: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia (1993) 7(Suppl. 1):21-29.
-
(1993)
Leukemia
, vol.7
, Issue.SUPPL. 1
, pp. 21-29
-
-
SILVERMAN, L.R.1
HOLLAND, J.F.2
WEINBERG, R.S.3
-
17
-
-
0002858015
-
Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921
-
SILVERMAN LR, HOLLAND JF, DEMAKOS EP et al.: Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann. Hematol. (1994) 68(Suppl. 1):A12.
-
(1994)
Ann. Hematol
, vol.68
, Issue.SUPPL. 1
-
-
SILVERMAN, L.R.1
HOLLAND, J.F.2
DEMAKOS, E.P.3
-
18
-
-
0025831445
-
Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes
-
CHITAMBAR CR, LIBNOCH JA, MATTHAEUS WG et al.: Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am. J. Hematol. (1991) 37:100-104.
-
(1991)
Am. J. Hematol
, vol.37
, pp. 100-104
-
-
CHITAMBAR, C.R.1
LIBNOCH, J.A.2
MATTHAEUS, W.G.3
-
19
-
-
0037093195
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
-
SILVERMAN LR, DEMAKOS EP, PETERSON BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. (2002) 20:2429-2440.
-
(2002)
J. Clin. Oncol
, vol.20
, pp. 2429-2440
-
-
SILVERMAN, L.R.1
DEMAKOS, E.P.2
PETERSON, B.L.3
-
20
-
-
0037092962
-
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: A cancer and leukemia group B study
-
KORNBLITH AB, HERNDON JE, SILVERMAN LR et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a cancer and leukemia group B study. J. Clin. Oncol. (2002) 20:2441-2452.
-
(2002)
J. Clin. Oncol
, vol.20
, pp. 2441-2452
-
-
KORNBLITH, A.B.1
HERNDON, J.E.2
SILVERMAN, L.R.3
-
21
-
-
33748474416
-
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the cancer and leukemia group B
-
SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J. Clin. Oncol. (2006) 24:3895-3903.
-
(2006)
J. Clin. Oncol
, vol.24
, pp. 3895-3903
-
-
SILVERMAN, L.R.1
MCKENZIE, D.R.2
PETERSON, B.L.3
-
22
-
-
0036342388
-
Treatment of myelodysplastic syndromes with 5-azacytidine
-
GRYN J, ZIEGLER Z, SHADDUCK R et al.: Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk. Res. (2002) 26:893-897.
-
(2002)
Leuk. Res
, vol.26
, pp. 893-897
-
-
GRYN, J.1
ZIEGLER, Z.2
SHADDUCK, R.3
-
24
-
-
33750078985
-
Treatment of acute myelogenous leukemia with outpatient azacitidine
-
SUDAN N, ROSSETTI JM, SHADDUCK R et al.: Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer (2006) 107:1839-1843.
-
(2006)
Cancer
, vol.107
, pp. 1839-1843
-
-
SUDAN, N.1
ROSSETTI, J.M.2
SHADDUCK, R.3
-
25
-
-
79960971189
-
Transcription modulation; a pilot study of sodium phenylbutyrate plus 5-azacytidine
-
CAMACHO L, RYAN HJ, CHANEL S et al.: Transcription modulation; a pilot study of sodium phenylbutyrate plus 5-azacytidine. Blood (2001) 98(Suppl. 1):A460.
-
(2001)
Blood
, vol.98
, Issue.SUPPL. 1
-
-
CAMACHO, L.1
RYAN, H.J.2
CHANEL, S.3
-
26
-
-
79960971544
-
A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies
-
MILLER CB, HERMAN JG, BAYLIN SB et al.: A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies. Blood (2001) 98(Suppl. 1):A622.
-
(2001)
Blood
, vol.98
, Issue.SUPPL. 1
-
-
MILLER, C.B.1
HERMAN, J.G.2
BAYLIN, S.B.3
-
27
-
-
34848865289
-
Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
-
Abstract
-
GARCIA-MANERO G, YANG AS, GILES F et al.: Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood (2006) 108:(Abstract 1954).
-
(1954)
Blood
, vol.108
-
-
GARCIA-MANERO, G.1
YANG, A.S.2
GILES, F.3
-
28
-
-
40949157668
-
Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
-
Abstract 7083
-
LYONS RM, COSGRIFF T, MODI S et al.: Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. ASCO Annual Meeting Proceedings (2007) 25:(Abstract 7083).
-
(2007)
ASCO Annual Meeting Proceedings
, vol.25
-
-
LYONS, R.M.1
COSGRIFF, T.2
MODI, S.3
-
29
-
-
34848928673
-
G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine
-
Abstract 4868
-
ROSSETTI JM, FALKE E, SHADDUCK RK et al.: G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine. Blood (2006) 108:(Abstract 4868).
-
(2006)
Blood
, vol.108
-
-
ROSSETTI, J.M.1
FALKE, E.2
SHADDUCK, R.K.3
-
30
-
-
40949083161
-
-
G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine, Florence, Italy 2007, Poster presentation
-
FALKE E, ROSSETTI JM, SAHDDUCK RK et al.: G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine. The 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy (2007) (Poster presentation).
-
The 9th International Symposium on Myelodysplastic Syndromes
-
-
FALKE, E.1
ROSSETTI, J.M.2
SAHDDUCK, R.K.3
-
31
-
-
3142580475
-
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome
-
CUTLER CS, LEE SJ, GREENBERG P et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood (2004) 104:579-585.
-
(2004)
Blood
, vol.104
, pp. 579-585
-
-
CUTLER, C.S.1
LEE, S.J.2
GREENBERG, P.3
-
32
-
-
40949136638
-
Pre-transplant 5-azacitidine (Vidaza) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS)
-
Abstract 3664
-
FIELD T, PERKINS J, ALSINA M et al.: Pre-transplant 5-azacitidine (Vidaza) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS). Blood (2006) 108:(Abstract 3664).
-
(2006)
Blood
, vol.108
-
-
FIELD, T.1
PERKINS, J.2
ALSINA, M.3
-
33
-
-
72249095950
-
Maintenance therapy with 5-azacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high-risk myelodysplastic syndrome (MDS): A dose and schedule finding study
-
Abstract 3668
-
SORIANO A, CHAMPLIN R, MCCORMICK G et al.: Maintenance therapy with 5-azacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high-risk myelodysplastic syndrome (MDS): a dose and schedule finding study. Blood (2006) 108:(Abstract 3668).
-
(2006)
Blood
, vol.108
-
-
SORIANO, A.1
CHAMPLIN, R.2
MCCORMICK, G.3
|